Age in years, mean (SD) | 41.5 (11.0) | 39.8 (10.7) | 40.1 (10.9) |
Men, n (%) | 108 (69.7) | 114 (76.0) | 40 (78.4) |
Weight in kg, mean (SD) | 76.6 (13.5) | 77.3 (16.7) | 73.3 (13.3) |
Duration of disease in years, mean (SD) | 9.0 (8.7) | 10.0 (9.1) | 8.5 (6.8) |
Concomitant NSAIDs, n (%) | 124 (80.0) | 127 (84.7) | 40 (78.4) |
Concomitant oral corticosteroids, n (%) | 19 (12.3) | 16 (10.7) | 9 (17.6) |
Concomitant DMARDs(SSZ, HCQ and MTX), n (%) | 65 (41.9) | 55 (36.7) | 17 (33.3) |
History of uveitis, n (%) | 16 (10.3) | 17 (11.3) | 4 (7.8) |
History of inflammatory bowel disease, n (%) | 5 (3.2) | 0 (0) | 4 (7.8)* |
History of psoriasis, n (%) | 10 (6.5) | 8 (5.3) | 2 (3.9) |
BASFI score, mean (SD) | 60.6 (20.3) | 57.7 (20.1) | 59.7 (19.3) |
BASDAI score, mean (SD) | 62.4 (17.0) | 59.4 (16.7) | 61.1 (13.7) |
VAS physician global assessment, mean (SD) | 62.0 (14.8) | 60.7 (15.4) | 62.1 (16.2) |
VAS patient global assessment, mean (SD) | 68.1 (18.9) | 65.41 (18.1) | 66.2 (16.3) |
Swollen joints, mean (SD) | 1.4 (2.8) | 1.0 (2.9) | 0.7 (1.7) |
Patients with ⩾1 swollen joints, n (%) | 59 (38.06) | 35 (23.33) | 12 (23.53) |
Nocturnal back pain, mean (SD) | 64.9 (21.0) | 64.3 (21.7) | 62.5 (22.4) |
Total back pain, mean (SD) | 63.9 (19.2) | 63.5 (21.1) | 63.1 (18.4) |
C reactive protein level (mg/l), mean (SD) | 21.7 (24.6) | 19.8 (20.8) | 22.0 (22.9) |
Modified Schober’s test, mean (SD) | 2.7 (1.9) | 2.3 (2.1) | 2.1 (2.6) |
Chest expansion, mean (cm) (SD) | 3.6 (2.5) | 3.4 (1.7) | 3.5 (1.7) |
Occiput-to-wall measurement, mean (cm) (SD) | 4.4 (5.9) | 4.8 (5.5) | 5.8 (6.2) |